The International Mismatch Repair Consortium
The International Mismatch Repair Consortium (IMRC) is a collaboration of clinicians and scientists who have agreed to pool and analyse data on Lynch syndrome, a genetic predisposition to cancer caused by germline mutations in DNA mismatch repair genes or EPCAM deletion, with the rationale that research on this hereditary syndrome will benefit from large datasets from many countries. As of October 2017, the IMRC includes approximately 273 members from 122 centres/clinics in 29 countries throughout Africa, Asia, Australasia, Europe, and North and South America, who are involved in research or treatment of people with Lynch syndrome and their families. To date, there are six research projects registered at the IMRC: cancer risks for Lynch syndrome, classification of mismatch repair variants, genetic testing and screening practices, environmental and lifestyle modifiers of cancer risk, inherited methylation and cancer risks for family members of constitutional mismatch repair deficiency (CMMR-D) patients. The most significant project, in terms of data accrued, is the study of cancer risks for Lynch syndrome which mainly asks whether age-specific cumulative risk (penetrance) of cancers differs by country or geographic region. As of October 2017, almost 6200 pedigrees from investigators from approximately 24 countries have been submitted for penetrance analysis – see http://www.sphinx.org.au/imrc.
KeywordsColorectal cancer Lynch syndrome Penetrance MLH1 MSH2 MSH6 PMS2 EPCAM International Risk factors Cohort Family history
The National Health and Medical Research Council, Australia, has supported this research via a project grant and via research fellowships. We thank all researchers, clinicians and genetic counsellors at participating centres who have given their time and resources and the Lynch syndrome families.
- 7.Choi Y-H, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, et al. Penetrance of colorectal cancer among MLH1/ MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Prac. 2009;7:14. https://doi.org/10.1186/1897-4287-7-14.
- 11.Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464–72. https://doi.org/10.1136/gutjnl-2015-309675.
- 12.Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat. 2009;30(5):757–70. https://doi.org/10.1002/humu.20936.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum Mutat. 2013;34(1):200–9. https://doi.org/10.1002/humu.22213.CrossRefGoogle Scholar
- 20.van Vliet CM, Dowty JG, van Vliet JL, Smith L, Mead LJ, Macrae FA, et al. Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genes. Hum Mutat. 2011;32(2):207–12. https://doi.org/10.1002/humu.21408.
- 21.Green J, O'Driscoll M, Barnes A, Maher ER, Bridge P, Shields K, et al. Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum. 2002;45(9):1223–32. https://doi.org/10.1097/01.DCR.0000027034.98952.85.CrossRefPubMedGoogle Scholar
- 24.Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. https://doi.org/10.1016/S0140-6736(11)61049-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, et al. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. Br J Cancer. 2011;105(1):162–9. https://doi.org/10.1038/bjc.2011.172.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, et al. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res. 2010;16(4):1331–9. https://doi.org/10.1158/1078-0432.ccr-09-1877.CrossRefGoogle Scholar
- 30.Dashti SG, Buchanan DD, Jayasekara H, Ait Ouakrim D, Clendenning M, Rosty C, et al. Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. Cancer Epidemiol Biomark Prev. 2017;26(3):366–75. https://doi.org/10.1158/1055-9965.epi-16-0496.CrossRefGoogle Scholar
- 39.Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958–64. https://doi.org/10.1200/JCO.2011.39.5590.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Bonaiti B, Bonadona V, Perdry H, Andrieu N, Bonaiti-Pellie C. Estimating penetrance from multiple case families with predisposing mutations: extension of the ‘genotype-restricted likelihood’ (GRL) method. Eur J Hum Genet. 2011;19(2):173–9. https://doi.org/10.1038/ejhg.2010.158.CrossRefGoogle Scholar